Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 inhibition of IL-1β-mediated activation of NF-κB transcriptional activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,970.00 | |
50 mg | 8-10 weeks | $ 2,580.00 | |
100 mg | 8-10 weeks | $ 3,400.00 |
Description | ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 inhibition of IL-1β-mediated activation of NF-κB transcriptional activity. |
In vitro | ST2825 blocks IL-1R/TLR signaling by interfering with MyD88 homodimerization. ST2825 inhibits this interaction in a concentration-dependent manner with ~40% inhibition of dimerization at ST2825 (5 μM) and 80% inhibition at ST2825 (10 μM ) [1]. |
In vivo | ST2825 effectively reduces IL-1β-induced IL-6 production in mice through oral administration, showing significant inhibition at 100 and 200 mg/kg doses. Mice receive oral doses of ST2825 or vehicles, ranging from 50 to 200 mg/kg, five minutes before intraperitoneal (i.p.) injections of 20 μg/kg IL-1β [1]. |
Molecular Weight | 591.51 |
Formula | C27H28Cl2N4O5S |
CAS No. | 894787-30-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (169.06 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ST 2825 894787-30-5 Others ST-2825 ST2825 inhibitor inhibit